Observational analysis reveals median overall survival of 12.5 months in multiple myeloma patients, indicating critical need for new therapeutic targets.
Key Points
Median overall survival for multiple myeloma patients was 12.5 months, highlighting significant treatment challenges.
Patients had received a median of 5 prior treatments, with 90.3% classified as triple-class refractory.
Analysis across three European registries examined treatment outcomes post anti-BCMA therapy exposure.
Current dependence on chemotherapy and IMID/PI therapies underscores a gap in available treatment options.